http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2517232-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ff63f7f80dc75d4a82e2a4eb4fb49f9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate | 2014-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d020809ce568e18a445c5bcecb5c4ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01a60298201fd11b87f34a0efaa4f3a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c8ee82f25211977630dbc1f19e27c43 |
| publicationDate | 2015-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2517232-A |
| titleOfInvention | Formulation |
| abstract | A suspension comprising microgranules having bead sizes in the range of 100 to 1200 microns of a benzimidazole derivative suspended in a triglyceride ester of a fatty acid where the suspension is stable for at least 1 month. Preferably the benzimidazole derivative is provided in the form of enteric coated beads. The enteric coating may comprise one or more layers selected from a disintegrant layer, a sealing later, and a controlled release layer. Preferably the benzimidazole derivative is formed on a sugar core. Preferably the benzimidazole derivative is a proton pump inhibitor, and is preferably pantoprazole, lansoprazole, rabeprazole or especially omeprazole. Preferably the fatty acid is a C8-10 fatty acid. The suspension may comprise a preservative, preferably potassium sorbate. The suspension may comprise one or more rafting agents, preferably alginic acid. The suspension may be used in the treatment of dyspepsia, peptic ulcer disease, gastritis, gastroesophagael reflux disease, laryngopharyngeal reflux, gastric and duodenum ulceration, and Zollinger-Ellison syndrome. |
| priorityDate | 2013-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.